Grace Therapeutics, Inc. (GRCE)
GRCE Stock Price Chart
Explore Grace Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GRCE price movements and trends.
GRCE Company Profile
Discover essential business fundamentals and corporate details for Grace Therapeutics, Inc. (GRCE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Feb 2012
Employees
4.00
Website
https://www.acastipharma.comCEO
Prashant Kohli
Description
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
GRCE Financial Timeline
Browse a chronological timeline of Grace Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.13, while revenue estimate is $400.00k.
Earnings released on 18 Jun 2026
EPS came in at -$0.07 surpassing the estimated -$0.24 by +70.83%.
Earnings released on 12 Feb 2026
EPS came in at -$0.14 falling short of the estimated -$0.09 by -55.56%.
Earnings released on 13 Nov 2025
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%.
Earnings released on 12 Aug 2025
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%.
Earnings released on 23 Jun 2025
EPS came in at $0.06 surpassing the estimated -$0.20 by +132.35%.
Earnings released on 13 Feb 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%.
Earnings released on 13 Nov 2024
EPS came in at -$0.33 matching the estimated -$0.33.
Earnings released on 9 Aug 2024
EPS came in at -$0.24 surpassing the estimated -$0.27 by +9.43%.
Earnings released on 21 Jun 2024
EPS came in at -$0.17 surpassing the estimated -$0.35 by +51.43%.
Earnings released on 12 Feb 2024
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 13 Nov 2023
EPS came in at -$0.43 falling short of the estimated -$0.26 by -65.38%.
Earnings released on 11 Aug 2023
EPS came in at -$0.54 falling short of the estimated -$0.28 by -92.86%.
Stock split effective on 10 Jul 2023
Shares were split 1 : 6 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 23 Jun 2023
EPS came in at -$3.90 falling short of the estimated -$0.84 by -364.29%.
Earnings released on 14 Feb 2023
EPS came in at -$0.54 surpassing the estimated -$0.74 by +27.03%.
Earnings released on 14 Nov 2022
EPS came in at -$0.66 .
Earnings released on 11 Aug 2022
EPS came in at -$0.79 .
Earnings released on 21 Jun 2022
EPS came in at -$0.72 .
Earnings released on 14 Feb 2022
EPS came in at -$0.65 .
Earnings released on 10 Nov 2021
EPS came in at $0.23 .
Stock split effective on 31 Aug 2021
Shares were split 1 : 8 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 12 Aug 2021
EPS came in at -$1.10 .
GRCE Stock Performance
Access detailed GRCE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
